Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial evaluating the safety and efficacy of Anixa's chimeric endocrine receptor T-cell (CER-T) therapy in patients with ovarian cancer

Next Previous
Trial Profile

A phase 1 trial evaluating the safety and efficacy of Anixa's chimeric endocrine receptor T-cell (CER-T) therapy in patients with ovarian cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Feb 2025 According to an Anixa Biosciences media release, the company has published an article in the Breaking Cancer News, which highlights the groundbreaking clinical trial led by Dr. Robert Wenham, Chairman of the Department of Gynecologic Oncology at Moffitt Cancer Center, and Dr. Monica Avila, a leading gynecologic oncologist at Moffitt. The trial explores the use of chimeric antigen receptor-T cell (CAR-T) therapy to treat ovarian cancer.
  • 10 Oct 2022 According to an Anixa Biosciences media release, Dr. Robert Wenham is the principal investigator for this trial.
  • 10 Oct 2022 According to an Anixa Biosciences media release, this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top